# The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study

> **NCT07724951** · — · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Donafeinib
- **PROCEDURE:** Transcatheter arterial chemoembolization
- **DRUG:** PD-1 / PD-L1 monoclonal antibody
- **PROCEDURE:** Hepatic Artery Infusion Chemotherapy

## Key facts

- **NCT ID:** NCT07724951
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724951, "The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07724951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*